All Updates

All Updates

icon
Filter
Partnerships
Eli Lilly collaborates with OpenAI to overcome antimicrobial resistance using AI
AI Drug Discovery
Jun 25, 2024
This week:
Product updates
Pimax announces compact Dream Air VR headset for USD 1,900
Extended Reality
Dec 23, 2024
Funding
HuLoop raises Series A funding from Mighty Capital
Workflow Automation Platforms
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
Financial Wellness Tools
Dec 23, 2024
M&A
Fiserv to acquire Payfare for undisclosed sum to enhance embedded finance solutions
FinTech Infrastructure
Dec 23, 2024
Funding
Meight raises EUR 3.4 million in funding led by Cusp Capital
Smart Mobility Information
Dec 23, 2024
Regulation/policy
Desktop Metal sues Nano Dimension over merger compliance
Additive Manufacturing
Dec 23, 2024
Management news
Nexa3D scales back operations amid financial crisis
Additive Manufacturing
Dec 23, 2024
Funding
Fraction AI raises USD 6 million in pre-seed funding to scale hybrid data labeling
Machine Learning Infrastructure
Dec 23, 2024
Last week:
Partnerships
Rocket Lab launches sixth Synspective radar satellite as part of ongoing partnership
Space Travel and Exploration Tech
Dec 21, 2024
Partnerships
EHang partners with Changan Automobile to develop eVTOL aircraft for personal transportation
Passenger eVTOL Aircraft
Dec 21, 2024
AI Drug Discovery

AI Drug Discovery

Jun 25, 2024

Eli Lilly collaborates with OpenAI to overcome antimicrobial resistance using AI

Partnerships

  • Eli Lilly has partnered with AI company OpenAI to develop novel antimicrobials targeting drug-resistant pathogens. The terms and conditions of the agreement have not been disclosed.

  • Through this partnership, Eli Lilly will leverage OpenAI's GenAI technology to fast-track the discovery and production of novel therapeutics to address antimicrobial resistance (AMR). The collaborative effort aims to use GenAI to accelerate drug discovery and develop custom, purpose-built technologies to target drug-resistant pathogens.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.